ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2011
HLA-G regulators in cancer medicine: an outline of key requirements.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 18 citations in OpenAlex.
- Biological Characteristics of HLA-G and Its Role in Solid Organ Transplantation.Frontiers in immunology · 2022Review
- Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.Anatomy & cell biology · 2017Article
- The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review.Journal of immunology research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HLA-G is unique among the class I human leukocyte antigens. It plays a pivotal role in immune tolerance and a paradoxical role in therapies. Indeed, HLA-G expression is associated with a good prognosis in organ transplantation and an ominous prognosis in cancer. Recent progress has been made in HLA-G regulation identification, especially on human cell lines; however, little is known about their role in cancer therapy. Based on the role of HLA-G expression in cancer, we investigated the potential impact of the regulation of this expression on the outcome of some cancers. In this communication, we emphasize the importance of screening for HLA-G expression after cancer therapy. Future clinical trials could lead to a better understanding of the implication of HLA-G expression in cancer and lead to a better knowledge of cancer monitoring and recurrence. These studies could also implicate HLA-G as a therapeutic target in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.